Illumina ILMN Sequencing — Total Revenue
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Illumina in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Illumina’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Illumina's sequencing — total revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Illumina's sequencing — total revenue?
- Illumina (ILMN) reported sequencing — total revenue of $995M in Q1 2026.
- How has Illumina's sequencing — total revenue changed year-over-year?
- Illumina's sequencing — total revenue increased by 5.1% year-over-year, from $947M to $995M.
- What is the long-term trend for Illumina's sequencing — total revenue?
- Over 4 years (2021 to 2025), Illumina's sequencing — total revenue has grown at a -0.8% compound annual growth rate (CAGR), from $4.11B to $3.99B.
- What does sequencing — total revenue mean?
- This metric represents the total gross revenue generated by the core sequencing business segment, encompassing sales of genetic sequencing instruments, associated consumables, and related service contracts. It serves as the primary indicator of the company's market penetration and demand for its high-throughput and clinical diagnostic genomic platforms. Tracking this figure allows investors to assess the health of the core life sciences product portfolio independent of non-sequencing business lines.